menu

Quintiles Library

Show Filters
White Paper
Medical Science Liaisons (MSLs) play a vital role within medical affairs, generating and communicating scientific information to stakeholders. From 18-24 months before a product is launched, MSLs can facilitate discussions about unmet need and modes of action for new products. They apply this expertise through to launch and post launch activities, helping ensure access...
Explore More
White Paper
When the U.S. Patient Protection and Affordable Care Act (ACA) was passed in 2010, the view from Washington was that a broken and overly expensive healthcare system was going to finally have relief and be more accessible. While the focus of the bill was on enhanced access, predictions were made about how the U.S. healthcare system would transform to a value-based,...
Explore More
Article
Read how the “Use of Modelling for Better Diabetes Care” can help healthcare organizations improve diabetes care – better outcomes, better costs.  Published in Asia Pacific Biotech News, the article details the rising burden of diabetes in Asia and how the QuintilesIMS CORE Diabetes Model can help stakeholders analyze the costs and benefits of competing interventions,...
Explore More
Fact Sheet
QuintilesIMS and Perspectum Diagnostics have established a partnership to help optimize the value of your NASH products by enhancing and accelerating the planning, execution and patient experience of clinical trials.
Read More
White Paper
This white paper authored by Launch Excellence Principals Ester Oben Etah and Bill McClellan takes a closer look at funding strategies for companies launching products for the first time. Does partnering or "Going it Alone" make more sense for emerging companies?
Explore More
Presentation
Manufacturers traditionally design randomized controlled trials (RCTs) to evaluate either the effectiveness of interventions in real-life routine practice conditions (pragmatic) or the efficacy of an intervention (explanatory). Both are critical to developing the right evidence for your product, but manufacturers are looking for ways to conduct them in parallel to support...
Explore More
White Paper
This insight brief provides a summary of the proposed legislation and potential impacts on oncology development programs if adopted. It also examines specific considerations and planning for pediatric oncology trials, and the changing landscape in pediatric oncology drug development.
Explore More
Infographic
The number of therapeutic options in cancer care is growing, and with it the complexity of treatment. Doctors are now faced with various decisions and choices from combinations of well-known drugs to precision medicines and personalized treatments, such as immunotherapies or even cell-based therapies. Some may come with complex changes to clinical pathways, or unfamiliar...
Read More
Fact Sheet
Patient expectations and choices are increasingly important in healthcare. However safe and effective a drug is in clinical trials, if patients choose not to take it in the real world, then biopharma, patients and healthcare systems all lose out. Discrete Choice Experiments offers a solution. ‘Discrete Choice Experiments’ (DCE) can help you find out which...
Read More
Fact Sheet
Product launches are notoriously difficult, with most brands not achieving their year one forecast. With so much at stake, being armed with sound strategies and an agile approach to get to market and realize value quickly can make all the difference. With our deep therapeutic and commercial expertise – powered by advanced, actionable analytics – QuintilesIMS helps pave...
Read More
Article
In an article published in the February 2017 issue of International Clinical Trials, Stewart Rosen and Nicola Smith discuss the challenge of patient recruitment for clinical trials and using clinical trial educators to help investigators with enrollment targets. This article is taken from International Clinical Trials February 2017, pages 44-47. © Samedan Ltd
Explore More
Article
Life science companies that are pouring millions of dollars into clinical R&D simply cannot afford a false start. Done right, 3D outsourcing not only speeds market launch but it can also help a new medicine outperform expectations by facilitating rapid and more widespread uptake by healthcare professionals and even patients. Authors: Paul Harney and Steve DeVrieze - IES,...
Explore More
White Paper
Biopharma companies can no longer take for granted that the incremental benefit or improved mode of action of a new therapy will lead to widespread uptake. Patient support programs (PSPs), offered by biopharma, are not yet commonplace, however, where they do exist they must be designed and then evolve to measure outcomes and demonstrate value. This is in response to...
Explore More
Fact Sheet
QuintilesIMS provides a technology solution powered by the Quintiles Infosario® Outcome system to assist registry sponsors in fulfilling the latest QCDR government regulations.
Read More
Fact Sheet
QuintilesIMS is the leading provider of registries and web-based solutions for measuring, improving and reporting on quality of care and patient outcomes. We have worked with medical and surgical specialty societies, associations and health care foundations since 1998 and have a dedicated division focused exclusively on this sector.
Read More
Infographic
Does social media matter to pharma? Only 50% of pharmaceutical companies are listening to their constituents on social media, and even fewer are engaging their targeted audiences. We think social media does matter read this infographic to see why.
Read More
White Paper
Life science companies that are pouring millions of dollars into clinical R&D simply cannot afford a false start. Done right, 3D outsourcing not only speeds market launch but it can also help a new medicine outperform expectations by facilitating rapid and more widespread uptake by healthcare professionals and even patients.
Explore More
White Paper
Biosimilar products must be structurally and functionally similar to their reference product. This seemingly simple expectation necessitates a unique developmental approach, which is distinct from traditional product development. The emphasis in biosimilar development lies with analytical proof of similarity, as this is the most sensitive tool to detect differences...
Explore More
White Paper
Recruitment of a sufficiently large number of participants into clinical trials can be a challenge in multiple therapeutic areas, and this has become particularly true for multiple sclerosis trials. For many reasons, the protocols for these trials have become very complex, and hence demanding on participants. A central difficulty in recruitment is identifying eligible...
Explore More
Infographic
Extraordinary discoveries are transforming the approach to cancer care – and immunotherapy is one of the most promising avenues of research. QuintilesIMS identifies the top 5 challenges in executing immune-oncology clinical trials, and innovative solutions to address those needs.
Read More